December 3, 2010 (December 13th, 2010)
As you know, your employment with Insmed Incorporated (the "Company") is being terminated in connection with the merger by and between the Company and Transave, Inc. (the "Merger"), and such termination is deemed to be a Qualifying Termination pursuant to Section 5 of that certain Agreement, dated June 22, 2007, between you and the Company (the "Change in Control Agreement"). To ensure that your separation from the Company occurs on mutually acceptable terms, this separation and release agreement will summarize the terms and conditions surrounding your separation including, without limitation, the compensation and benefits that will be provided to you.
Agreement (August 4th, 2010)
This Agreement dated as of June 22, 2007, is entered into by and between Steve Glover ("Employee") and Insmed Incorporated, a Virginia corporation ("Insmed").
Auriga Laboratories – Indemnification Agreement (October 19th, 2006)
THIS AGREEMENT (the Agreement) is made and entered into as of ____________, 2006 between Auriga Laboratories, Inc., a Delaware corporation (the Company), and Steve Glover, its affiliates, directors, officers, employees, members or agents (collectively the Indemnitee).
Auriga Laboratories – Contract (October 19th, 2006)
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
Auriga Laboratories – [AURIGA LABS HEADER] September 25, 2006 Dear Steve: (October 19th, 2006)
It is with great pleasure that I welcome you (You or Director) to the Board of Directors (Board) of Auriga Laboratories, Inc. (Auriga or the Company) effective November 1, 2006. This letter agreement contains the terms and conditions of your directorship.
Andrx – Agreement to License and Purchase (May 4th, 2005)
THIS AGREEMENT, dated March 2, 2005, is entered into by and between Andrx Labs, LLC, a Delaware limited liability company, Andrx Laboratories, Inc., a Mississippi corporation, Andrx Laboratories (NJ), Inc., a Delaware corporation, and Andrx EU Ltd., a United Kingdom company (each, a Seller and collectively, the Seller Entities), and First Horizon Pharmaceutical Corporation, a Delaware corporation (Buyer).